Trial reportClinical medicine & research2009
The effect of an inhaled corticosteroid on glucose control in type 2 diabetes.
Trial report in Clinical medicine & research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Tailored or adapted interventions for adults with chronic obstructive pulmonary disease and at least one other long-term condition: a mixed methods review.The Cochrane database of systematic reviews · 2021Pooled it
- Diabetes-inducing effects of bronchial asthma.World journal of diabetes · 2025Article
- Exploring the association between asthma and chronic comorbidities: impact on clinical outcomes.Frontiers in medicine · 2024Review
- Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review.World journal of diabetes · 2023Review
- STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life.BMC pulmonary medicine · 2022Article
- Combination therapies with thiazolidinediones are associated with a lower risk of acute exacerbations in new-onset COPD patients with advanced diabetic mellitus: a cohort-based case-control study.BMC pulmonary medicine · 2021Article
- Association between Asthma and Type 2 Diabetes Mellitus: Mechanisms and Impact on Asthma Control-A Literature Review.Canadian respiratory journal · 2021Review
- Observational
- The use of inhaled corticosteroids in pediatric asthma: update.The World Allergy Organization journal · 2016Review
- Effect of inhaled corticosteroids on glycemic status.The open respiratory medicine journal · 2014Article
- Systemic effects of inhaled corticosteroids: an overview.The open respiratory medicine journal · 2014Article
- Influence of chronic comorbidity and medication on the efficacy of treatment in patients with diabetes in general practice.The British journal of general practice : the journal of the Royal College of General Practitioners · 2013Article
- Prediction of drug-target interactions and drug repositioning via network-based inference.PLoS computational biology · 2012Article
- Corticosteroids affect nitric oxide generation, total free radicals production, and nitric oxide synthase activity in monocytes of asthmatic patients.Molecular and cellular biochemistry · 2011Article
- The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.International journal of chronic obstructive pulmonary disease · 2010Review
- Article
- [Comprehensive approach to comorbidities in COPD: expert recommendations].Open respiratory archivesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the effect of inhaled corticosteroid (ICS) therapy on glucose control in adults with type 2 diabetes mellitus and coexisting asthma or chronic obstructive pulmonary disease (COPD).
designA prospective randomized, double-blind, double-dummy placebo-controlled, crossover investigation of inhaled steroids and oral leukotriene blockers.
settingA United States Department of Veterans Affairs Health Care System outpatient setting.
participantsAdults with type 2 diabetes and asthma or COPD.
methodsSubjects (n=12) were randomized to receive either inhaled fluticasone propionate (440 microg twice daily) and oral placebo, or inhaled placebo and oral montelukast (10 mg/day). After 6 weeks, subjects were switched to the opposite therapy for 6 weeks. The primary outcome measure was the change in the percentage of glycosylated hemoglobin (%HbA1c) at 6 weeks relative to the baseline value.
resultsTen patients completed the study. The difference between the mean within-subject changes in %HbA1c associated with 6-week periods of fluticasone and the mean changes associated with montelukast therapy was small but statistically significant (mean difference=0.25; P<0.025). Neither fluticasone nor oral montelukast therapy for 6 weeks led to a significantly different mean % HbA1c compared with the relevant baseline (mean differences=0.11 and -0.14, respectively).
conclusionThe absence of a clinically significant within-subject difference in the changes in %HbA1c associated with fluticasone versus oral montelukast therapy, or between either therapy or baseline does not warrant recommending changes in therapy for asthma or diabetes in patients with these co-morbid conditions. However, we suggest that clinicians carefully monitor blood glucose control when diabetic patients initiate ICS, especially with higher dosages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.